In August, John Newell of John Newell & Associates shared the below chart for Allied Gold Ltd. (ALG:TSX; AGLD:LSE; ALD:ASX).
As you can see, in this chart, Newell gives a first price target of CA$3.80, a second target of CA$4.60, and a third target of CA$5.50. Newell's overall big-picture target was CA$7.65.
Newell recently shared the updated chart below.
Above, he notes that Allied Gold had surpassed his first target. This was done by the close of January 23, 2025, when the stock closed at CA$3.92.
Yesterday, January 30, 2025, Allied Gold closed on the second target at CA$4.60.
Newell has kept his original third target, and his big-picture target is still CA$7.65.
Want to be the first to know about interesting Gold investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
-
Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.